Skip to main content
メニュー
Revvity logo
Contact us

Loading...

JP
Search all

Loading...

Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • Products
  • 研究・開発
  • タンパク質解析
    • ゲノム解析
    • タンパク質解析
    • 細胞分析
    • 研究ソリューション
  • イムノアッセイ
    • Binding Assays
    • イムノアッセイ
    • マイクロ流体によるタンパク質特性評価
    • Microplate Readers
    • マイクロプレート
    • Recombinant Proteins
    • ウェスタンブロッティング
    • Sample Dissociation
    • M-PVA Magnetic Beads
  • Reagents for Receptor Binding
    • Autoimmune Disease Research Reagents
    • MASLD, MASH, and Fibrosis Research Reagents
    • Cell Signaling Research Reagents
    • Biologics Screening and Characterization Assays
    • Cell and Gene Therapy Research Reagents
    • Obesity, Diabetes and Metabolic Disease Reagents
    • Newest assay kits
    • Reagents for Deciphering the Interactome
    • Reagents for Fibrosis Research
    • Reagents for Receptor Binding
    • Alphaアッセイ
    • HTRF
    • LANCE
    • DELFIA
    • GPCR research reagents
    • Biomarker detection reagents
    • Cytokine Research Reagents
    • Epigenetic research reagents
    • Protein kinase research reagents
    • Protein-protein interaction research reagents
    • Target engagement reagents
    • Targeted Protein Degradation
    • Immuno-oncology Reagents
    • Neuroscience Research Reagents
    • Virology Reagents
    • Oncology Drug Discovery Reagents

Reagents for Receptor Binding

View products & services View resource library
Tag-lite, ligand binding technology

Tag-lite demonstrates its effectiveness in the lab, taking the lead over traditional SPA and radioligand binding assays.

  • No separation steps
  • Cell-based solutions
  • No radioactive waste
  • Small quantities of labelled ligands

For research use only. Not for use in diagnostic procedures.

Shop now
receptor-binding-872x872

18 verified receptors, and counting

Revvity scientists have verified 18 Tag-lite binding assays as of this writing. If the receptor you wish to study is not listed, remember that Revvity’s team of experienced experts work with clients to create custom binding solutions. All ligand binding assays listed here include labeled cells and their matching fluorescent ligands.

Kinetic binding and residence time

Growing evidence suggests that ligand–receptor binding kinetics is an overlooked factor in drug discovery. Revvity has developed Tag-lite™ kits and services to address the kinetic binding needs of GPCR researchers around the world.

Binding kinetics relates to the rate of association and dissociation of a drug-protein complex. Binding kinetics is thought to be a critical parameter for optimizing the in vivo efficacy of drug candidates. As such, kinetics is receiving increasing attention in drug discovery efforts. Tag-lite combines the flexibility of a radioligand binding with the advantages of homogeneous nonradioactive technologies such as SPR. The homogeneous character of Tag-lite enables binding events to be monitored continually without ever having to stop the reaction.

Motulsky and Mahan described equations that could be used for studying the kinetics of competitive binding. Fitting of data using Tag-lite to these equations allows the determination of the association and dissociation rate constants of the unlabeled competing ligand.

Using Tag-lite and a Motulsky & Mahan equations, the Kon and Koff of 2 muscarinic M1 receptor bindiners were calculated (Atropine and Pirenzepine):

lookbook-binding-tag-lite_assay-performance-telezenpine-atropine
lookbook-binding-tag-lite_assay-performance-telezenpine-pirenzepine

Binding assay: do it yourself

Tag-lite offers freedom and flexibility to build up your assays from target construction to assay development.

A plasmid construction is engineered with Tag-lite plasmids and the gene encoding your protein of interest. Once transfected into cells, these plasmids lead to the expression of a protein fused with the tag. The tagged protein covalently and specifically interacts with Tag-lite substrates.

Build your target with Tag-lite plasmids

Revvity has optimized a plasmid encoding SNAP bordered by restriction sites, for cloning a gene of interest. By using this plasmid, a construction can be engineered. This construction encodes for the protein of interest and SNAP-Tag in the N or C terminal position.

Label your tagged target with Tag-lite substrates

A selection of substrates labeled with HTRF fluorophores is also proposed for SNAP-tag.

1.Plasmid selection

Choose an empty plasmid among the 3 different selection markers: Hygromycin, Neomycin, Zeocin. 

lookbook-binding-tag-lite-step-1

2.GPCR cloning

Using standard cloning techniques, insert the GPCR gene of interest into the empty plasmid.

lookbook-binding-tag-lite-step-2

3.Cell transfection

Using standard transfection techniques, transiently express the TAG-GPCR of interest in your cell line.

lookbook-binding-tag-lite-step-3

4.Cell labeling

Use one of the appropriate TAG substrates to specifically and covalently label the TAG-GPCR with a cryptate donor.

lookbook-binding-tag-lite-step-4

5.Binding assays

Perform the binding assay you designed and built!

lookbook-binding-tag-lite-step-5
bg-element-listing-page bg-element-listing-page-mobile
Products & services
Resource library
Revvity Logo

Loading...

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.